How do I install the Endo Paget Lsc Biomarker Interpretation skill?

Run npx skillmds@latest add dromlakhani/endo-paget-lsc-biomarker-interpretation in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Paget Lsc Biomarker Interpretation safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Paget Lsc Biomarker Interpretation?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Paget Lsc Biomarker Interpretation free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Paget Lsc Biomarker Interpretation?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Paget Lsc Biomarker Interpretation by dromlakhani

Name: Endo Paget Lsc Biomarker Interpretation
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo Paget Lsc Biomarker Interpretation

Uses the least significant change (LSC) derived from analytical and biological variation to determine whether two sequential bone turnover marker measurements reflect a true biological difference. Triggers include when monitoring biomarker trends to assess treatment response or disease progression in Paget’s disease.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Interpret bone turnover marker change using least significant change

STEP 1 — Gather Information

Collect two sequential measurements of the same bone turnover marker (e.g., serum total ALP, BSAP, P1NP, NTx, or CTx) obtained under comparable conditions (same assay platform, fasting status, time of day). Record the analytical coefficient of variation (CVa) and within‑subject biological variation (CVg) for the marker from laboratory validation data or published sources.

STEP 2 — Rule In / Rule Out

Calculate the least significant change (LSC) using the formula LSC = 2.77 × √(CVa² + CVg²) (where 2.77 corresponds to a 95% confidence level for two measurements). If the absolute percent change between the two results exceeds the LSC, rule in a true biological change; otherwise, rule out that the observed difference is likely due to measurement variability.

STEP 3 — Classify or Stratify

Express the change as a ratio to LSC (Δ/LSC). A ratio >1 indicates a statistically significant change; further classify direction: a decrease >LSC suggests treatment effect or disease attenuation, while an increase >LSC suggests disease progression or non‑adherence. If the ratio is ≤1, consider the change indeterminate and recommend repeat testing.

STEP 4 — Decide

If a significant decrease is confirmed, continue current therapy and schedule next assessment per drug‑specific interval (e.g., 6–12 weeks for resorption markers, 2–3 months for formation markers). If a significant increase is observed, evaluate for treatment failure, non‑adherence, or complications and consider intensifying therapy or investigating alternative causes. If indeterminate, repeat the marker in 1–3 months before making therapeutic changes.

Clinical Guardrails / Mimics / Pitfalls

Do not interpret changes that fall within the LSC as clinically meaningful; avoid making therapeutic decisions based on single‑marker fluctuations. Be aware of assay‑specific variability: total ALP has higher biological variation than specific markers (BSAP, P1NP, NTx) and may require larger changes to exceed LSC. Ensure samples are processed on the same automated platform to minimize analytical variation; urine markers show greater within‑subject variability than serum markers.

Concrete Clinical Example

A patient with active Paget’s disease has serum NTx of 65 nM BCE at baseline and 48 nM BCE after 3 months of zoledronate. Laboratory CVa for NTx is 5% and CVg is 12%. LSC = 2.77 × √(0.05² + 0.12²) ≈ 2.77 × 0.13 ≈ 0.36 (36%). Percent change = (48‑65)/65 ×100 = ‑26%. Since |‑26%| < 36%, the change does not exceed LSC; thus the decrease is not statistically significant and treatment effect cannot be confirmed based on NTx alone.

Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, https://doi.org/10.1210/jc.2014-2910

TODO: consider adding scripts/calc.py for the endo-paget-lsc-biomarker-interpretation calculator

---name: endo-paget-lsc-biomarker-interpretationdescription: Uses the least significant change (LSC) derived from analytical and biological variation to determine whether two sequential bone turnover marker measurements reflect a true biological difference. Triggers include when monitoring biomarker trends to assess treatment response or disease progression in Paget’s disease.---# Interpret bone turnover marker change using least significant change## STEP 1 — Gather InformationCollect two sequential measurements of the same bone turnover marker (e.g., serum total ALP, BSAP, P1NP, NTx, or CTx) obtained under comparable conditions (same assay platform, fasting status, time of day). Record the analytical coefficient of variation (CVa) and within‑subject biological variation (CVg) for the marker from laboratory validation data or published sources.## STEP 2 — Rule In / Rule OutCalculate the least significant change (LSC) using the formula LSC = 2.77 × √(CVa² + CVg²) (where 2.77 corresponds to a 95% confidence level for two measurements). If the absolute percent change between the two results exceeds the LSC, rule in a true biological change; otherwise, rule out that the observed difference is likely due to measurement variability.## STEP 3 — Classify or StratifyExpress the change as a ratio to LSC (Δ/LSC). A ratio >1 indicates a statistically significant change; further classify direction: a decrease >LSC suggests treatment effect or disease attenuation, while an increase >LSC suggests disease progression or non‑adherence. If the ratio is ≤1, consider the change indeterminate and recommend repeat testing.## STEP 4 — DecideIf a significant decrease is confirmed, continue current therapy and schedule next assessment per drug‑specific interval (e.g., 6–12 weeks for resorption markers, 2–3 months for formation markers). If a significant increase is observed, evaluate for treatment failure, non‑adherence, or complications and consider intensifying therapy or investigating alternative causes. If indeterminate, repeat the marker in 1–3 months before making therapeutic changes.## Clinical Guardrails / Mimics / PitfallsDo not interpret changes that fall within the LSC as clinically meaningful; avoid making therapeutic decisions based on single‑marker fluctuations. Be aware of assay‑specific variability: total ALP has higher biological variation than specific markers (BSAP, P1NP, NTx) and may require larger changes to exceed LSC. Ensure samples are processed on the same automated platform to minimize analytical variation; urine markers show greater within‑subject variability than serum markers.## Concrete Clinical ExampleA patient with active Paget’s disease has serum NTx of 65 nM BCE at baseline and 48 nM BCE after 3 months of zoledronate. Laboratory CVa for NTx is 5% and CVg is 12%. LSC = 2.77 × √(0.05² + 0.12²) ≈ 2.77 × 0.13 ≈ 0.36 (36%). Percent change = (48‑65)/65 ×100 = ‑26%. Since |‑26%| < 36%, the change does not exceed LSC; thus the decrease is not statistically significant and treatment effect cannot be confirmed based on NTx alone.**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, https://doi.org/10.1210/jc.2014-2910> **TODO:** consider adding scripts/calc.py for the endo-paget-lsc-biomarker-interpretation calculator

Frequently asked questions